Shionogi & Co., Ltd. (SGIOF) Stock Price, News & Analysis

Company Overview

Shionogi & Co., Ltd. is a research-driven pharmaceutical company headquartered in Osaka, Japan, with origins dating back to 1878. The company concentrates on the discovery, development and sale of prescription medicines in key therapeutic areas, including infectious diseases, pain management, cardiovascular and metabolic disorders, central nervous system disorders and oncology. Shionogi’s mission emphasizes addressing unmet medical needs, particularly in the field of antimicrobial resistance, where it has developed both small-molecule antibiotics and novel treatment approaches.

The firm’s product portfolio comprises marketed therapies such as Cresemba (isavuconazole) for invasive fungal infections, and Fetroja (cefiderocol), a siderophore cephalosporin antibiotic for multidrug-resistant Gram-negative infections. Shionogi also co-develops and licenses compounds in collaboration with global partners, leveraging alliances with leading pharmaceutical companies across North America, Europe and Asia. Its pipeline includes candidates targeting pain, metabolic disease and oncology indications, reflecting a balanced strategy of in-house research and strategic partnerships.

Shionogi conducts its research and development through facilities in Japan and overseas, with key affiliates and subsidiaries in the United States, the United Kingdom, China and Australia. The company’s international footprint is supported by manufacturing sites compliant with global regulatory standards. Governance is overseen by a board of directors and executive officers, who guide Shionogi’s long-term strategy focused on innovative drug discovery, sustainable business growth and contributions to public health worldwide.

Key Stats

• Today's Range: $17.68 to $17.68
• 50-Day Range: $17.68 to $23.63
• 52-Week Range: $14.25 to $26.00
• Volume: 600 shs
• Average Volume: 2,865 shs
• Market Capitalization: N/A
• P/E Ratio: 0.19
• Dividend Yield: 108.03%
• Price Target: N/A
• Consensus Rating: N/A

Shionogi & Co., Ltd. Stock Analysis - MarketRank™

Shionogi & Co., Ltd. scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Shionogi & Co., Ltd..

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Shionogi & Co., Ltd. is 0.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shionogi & Co., Ltd. is 0.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.58.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Shionogi & Co., Ltd. has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in Shionogi & Co., Ltd. has recently increased by 4.85%, indicating that investor sentiment is decreasing.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Shionogi & Co., Ltd. pays a meaningful dividend of 1.14%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Shionogi & Co., Ltd. does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Shionogi & Co., Ltd. is 21.00%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 0.9 / 5
• News Sentiment: N/A

News Sentiment

Shionogi & Co., Ltd. has a news sentiment score of -0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Shionogi & Co., Ltd. this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shionogi & Co., Ltd. insiders have not sold or bought any company stock.

Percentage Held by Institutions

22.59% of the stock of Shionogi & Co., Ltd. is held by institutions.

Company Calendar

• Today: 5/19/2026
• Next Earnings (Estimated): 8/03/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:SGIOF
• CIK: 1281721
• Web: www.shionogi.co.jp
• Phone: (166) 202-2161
• Fax: N/A
• Employees: 5,690
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.19
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A